Epimedium(Ahịhịa Horny Goat) wepụ- Icariin ghọrọ olileanya ọhụrụ n'ịlụso ọrịa cancer ọgụ urothelial ọgụ.

Urothelial carcinoma bụ otu n'ime ọrịa cancer nke urinary a na-ahụkarị, na nlọghachite etuto na metastasis bụ isi ihe na-achọpụta ihe. N'afọ 2023, a ga-achọpụta ihe dị ka 168,560 ọrịa kansa urinary na United States, na-egbu ihe dịka 32,590; Ihe dịka 50% nke ikpe ndị a bụ carcinoma urothelial. N'agbanyeghị na enwere nhọrọ ọgwụgwọ ọhụrụ, dị ka chemotherapy dabere na platinum na immunotherapy nke PD1, ihe karịrị ọkara nke ndị ọrịa carcinoma urothelial anabataghị ọgwụgwọ ndị a. Ya mere, ọ dị mkpa ngwa ngwa iji nyochaa usoro ọgwụgwọ ọhụrụ iji meziwanye prognosis nke ndị ọrịa urothelial carcinoma.

Icariin(ICA), ihe bụ isi na-arụsi ọrụ ike na Epimedium, bụ tonic, aphrodisiac, na ọgwụ ọdịnala ndị China na-egbochi rheumatic. Ozugbo etinyere ya, ICA na-eme ka ọ bụrụ icartin (ICT), nke na-arụ ọrụ ya. ICA nwere ọtụtụ ihe omume dị ndụ, gụnyere ịhazi ihe mgbochi mgbanwe, inwe ihe ndị na-akpata antioxidant, na igbochi ọganihu etuto ahụ. Na 2022, Icaritin capsules nwere ICT dị ka ihe bụ isi ihe ndị China National Medical Product Administration (NMPA) kwadoro maka ọgwụgwọ nke mbụ nke ọrịa cancer hepatocellular na-adịghị arụ ọrụ. Na mgbakwunye, ọ gosipụtara nrụpụta dị ukwuu n'ịgbatị ogologo ndụ nke ndị ọrịa nwere carcinoma hepatocellular dị elu. Ọ bụghị nanị na ICT na-egbu etuto ahụ kpọmkwem site n'ịkwalite apoptosis na autophagy, kamakwa ọ na-achịkwa microenvironment na-alụso ọrịa ọgụ tumo ma na-akwalite nzaghachi mgbochi ọrịa tumor. Agbanyeghị, aghọtachaghị usoro nke ICT ji chịkwaa TME, ọkachasị na carcinoma urothelial.

N'oge na-adịbeghị anya, ndị na-eme nchọpụta sitere na Ngalaba Urology, Ụlọ Ọgwụ Huashan, Mahadum Fudan bipụtara otu isiokwu isiokwu ya bụ "Icaritin na-egbochi ọganihu nke ọrịa cancer urothelial site n'ịkwụsị PADI2-mediated neutrophil infiltration na neutrophil extracellular trap formation" na akwụkwọ akụkọ Acta Pharm Sin B. Ọmụmụ ahụ kpughere. naicariinMbelata nke ukwuu mgbasa na ọganihu etuto ahụ ka ọ na-egbochi infiltration neutrophil na njikọ NET, na-egosi na ICT nwere ike ịbụ ihe mgbochi NETs ọhụrụ na ọgwụgwọ ọhụrụ maka carcinoma urothelial.

Ntughari ntughari na metastasis bu isi ihe kpatara onwu na urothelial carcinoma. N'ime microenvironment tumor, ụmụ irighiri ihe na-adịghị mma na ọtụtụ mkpụrụ ndụ mgbochi ọrịa na-egbochi mgbochi antitumor. Ihe microenvironment na-egbuke egbuke, jikọtara ya na neutrophils na neutrophil extracellular traps (NET), na-akwalite metastasis tumor. Otú ọ dị, ọ dịghị ọgwụ ọ bụla ugbu a na-egbochi neutrophils na NET.

N'ime ọmụmụ ihe a, ndị nchọpụta gosipụtara na nke mbụ yaicariin, ọgwụgwọ nke mbụ maka ọrịa cancer hepatocellular dị elu na nke a na-apụghị ịgwọta, nwere ike ibelata NETosis nke NETosis igbu onwe ya ma gbochie ntinye neutrophil na microenvironment tumor. Mechanistically, ICT na-ejikọta ma na-egbochi okwu PADI2 na neutrophils, si otú a na-egbochi PADI2-mediated histone citrullination. Na mgbakwunye, ICT na-egbochi ọgbọ ROS, na-egbochi ụzọ mgbaàmà MAPK, ma na-egbochi metastasis tumor nke NET kpatara.

N'otu oge ahụ, ICT na-egbochi tumor PADI2-mediated histone citrullination, si otú a na-egbochi transcription nke neutrophil mbanye mkpụrụ ndụ ihe nketa dị ka GM-CSF na IL-6. N'aka nke ya, downregulation nke IL-6 okwu na-etolite a regulatory nzaghachi loop site JAK2/STAT3/IL-6 axis. Site na nyocha nyochaghachi nke ihe nlele ụlọ ọgwụ, ndị nyocha ahụ chọtara njikọ dị n'etiti neutrophils, NETs, ​​UCa prognosis na mgbapụ mgbochi. ICT jikọtara ya na ndị na-egbochi ebe nleba anya mgbochi ọrịa nwere ike inwe mmetụta synergistic.

Na nchịkọta, nchọpụta a chọpụtara naicariinMbelata nke ukwuu mgbasa na ọganihu etuto ahụ ka ọ na-egbochi infiltration neutrophil na njikọ NET, na neutrophils na NET na-ekere òkè na-egbochi ụbụrụ na-egbochi microenvironment tumor nke ndị ọrịa nwere carcinoma urothelial. Na mgbakwunye, ICT jikọtara ya na anti-PD1 immunotherapy nwere mmetụta synergistic, na-atụ aro usoro ọgwụgwọ nwere ike maka ndị ọrịa nwere carcinoma urothelial.